Asia Pacific Cell Therapy Manufacturers and Recent Developments

Who are the Market Top Companies and What are Their Offerings?

What are the Major Recent Developments in the Market?

• In November 2025, NexCAR19, the world’s first humanized CAR-T (Chimeric Antigen Receptor T-cell) therapy, developed by ImmunoACT, was launched in India. This therapy will be used to treat refractory or relapsed B-cell Acute Lymphoblastic Leukaemia and B-cell Non-Hodgkin’s Lymphoma cancers.
• In July 2025, the 3D FloTrix Experience Center was launched in Singapore by CytoNiche Biotech. This launch will also offer the technology used in China’s first-approved stem cell therapy, and will represent a crucial breakthrough in the firm’s expansion plan.

Market Value Chain Analysis

R&D

• The R&D of the Asia Pacific cell therapy focuses on the development of off-the-shelf allogeneic therapies, treatment for solid tumors, and automated manufacturing solutions.
• Key players: Legend Biotech, JW Therapeutics.

Clinical Trials and Regulatory Approvals

• The safety endpoints, long-term efficacy profiles, and manufacturing viability are evaluated in the clinical trials and regulatory approvals of the cell therapy in the Asia Pacific.
• Key players: Legend Biotech, JW Therapeutics.

Patient Support and Services

• The specialized apheresis logistics, localized payment assistant programs, and medical travel assistance are provided in the patient support and services for Asia Pacific cell therapy.
• Key players: Novartis, Gilead Sciences.

Market Growth

The Asia Pacific cell therapy market size was estimated at USD 0.99 billion in 2025 and is predicted to increase from USD 1.22 billion in 2026 to approximately USD 7.63 billion by 2035, expanding at a CAGR of 22.63% from 2026 to 2035.